D.A. Davidson & CO. Acquires 15,644 Shares of Guardant Health, Inc. $GH

D.A. Davidson & CO. grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 66.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 39,313 shares of the company’s stock after acquiring an additional 15,644 shares during the period. D.A. Davidson & CO.’s holdings in Guardant Health were worth $2,046,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of GH. Janney Montgomery Scott LLC bought a new position in shares of Guardant Health during the first quarter valued at $232,000. Oppenheimer & Co. Inc. bought a new position in shares of Guardant Health during the first quarter valued at $442,000. Lisanti Capital Growth LLC bought a new position in shares of Guardant Health during the first quarter valued at $1,337,000. Teacher Retirement System of Texas bought a new position in shares of Guardant Health during the first quarter valued at $866,000. Finally, Principal Financial Group Inc. raised its stake in shares of Guardant Health by 4,838.8% during the first quarter. Principal Financial Group Inc. now owns 498,129 shares of the company’s stock valued at $21,220,000 after acquiring an additional 488,043 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on GH. UBS Group lifted their target price on shares of Guardant Health from $70.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, September 25th. Raymond James Financial lifted their target price on shares of Guardant Health from $59.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, July 31st. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, September 25th. Stifel Nicolaus set a $73.00 target price on shares of Guardant Health in a research note on Thursday, September 25th. Finally, Mizuho lifted their target price on shares of Guardant Health from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Thursday, September 25th. Twenty-three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $67.29.

Insiders Place Their Bets

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the completion of the sale, the chief executive officer directly owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director owned 851 shares of the company’s stock, valued at $46,090.16. The trade was a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 302,691 shares of company stock valued at $17,984,628 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.

Guardant Health Trading Up 4.0%

NASDAQ:GH opened at $72.15 on Monday. The stock has a market capitalization of $9.00 billion, a price-to-earnings ratio of -21.54 and a beta of 1.53. The firm has a fifty day simple moving average of $62.25 and a two-hundred day simple moving average of $51.95. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $72.70.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. The company’s revenue for the quarter was up 31.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.84) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. Equities analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.